BILL ANALYSIS

HR9395

NEUTRAL

To amend title XVIII of the Social Security Act to require certain reporting with respect to agents and brokers of Medicare Advantage organizations.

HR9395 (To amend title XVIII of the Social Security Act to require certain reporting with respect to agents and brokers of Medicare Advantage organizations.) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare and Technology. View the full bill text on Congress.gov.

neutral

Market Sentiment

5/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR9395 is a low-impact, early-stage procedural bill targeting MA broker reporting.

No funding is authorized — the effect is purely regulatory compliance.

For UnitedHealthcare and other MA insurers, cost impact is immaterial (<0.5% of revenue).

How HR9395 Affects the Market

No actionable market implications. The bill does not change MA payment rates, star ratings, or regulatory structure in a material way. Insurers' MA margins remain driven by CMS reimbursement benchmarks and utilization trends, not broker reporting.

Bill Details

Metric	Value
Bill Number	HR9395
Market Sentiment	neutral
Event Date	June 23, 2026
Affected Sectors	Healthcare, Technology
Source	View on Congress.gov →

Summary

HR9395 is an early-stage bill requiring Medicare Advantage organizations to report on agent/broker activities. It carries no funding and has only been referred to committee. Its market impact is negligible — compliance costs for major insurers like UnitedHealthcare are de minimis relative to revenue.

Full AI Market Analysis

On June 23, 2026, Rep. Alexandria Ocasio-Cortez introduced HR9395 in the 119th Congress. The bill amends Title XVIII of the Social Security Act to impose reporting requirements on agents and brokers of Medicare Advantage (MA) organizations. It was referred to both the Ways and Means and Energy and Commerce Committees — standard for Medicare-related legislation. This is a very early stage; no committee hearings or votes have occurred. The bill authorizes no funding; it is a regulatory measure. For a major MA carrier like UnitedHealthcare (UNH), with ~$400B annual revenue, incremental compliance costs are trivial — likely under $200M annually if fully implemented. Other MA insurers (e.g., Humana, CVS/Aetna) could be similarly affected but the impact remains minor. Congress's agenda is crowded and this bill faces an uncertain path. No convergence with other signals was identified in the provided data.